Free Trial

Gerresheimer (ETR:GXI) Trading 2% Higher - Should You Buy?

Gerresheimer logo with Medical background

Key Points

  • Gerresheimer AG's stock price increased by 2% during trading, reaching a last price of €43.10 ($51.31) with a significant trading volume surge of 145% compared to its average.
  • The company has a market capitalization of $1.48 billion and a price-to-earnings ratio of 12.91, indicating potentially attractive valuation metrics for investors.
  • Gerresheimer specializes in manufacturing medicine packaging and drug delivery devices, operating through three key divisions that cater to both domestic and international markets.
  • Interested in Gerresheimer? Here are five stocks we like better.

Gerresheimer AG (ETR:GXI - Get Free Report) shot up 2% during trading on Tuesday . The company traded as high as €43.62 ($51.32) and last traded at €43.10 ($50.71). 345,089 shares were traded during mid-day trading, an increase of 145% from the average session volume of 140,925 shares. The stock had previously closed at €42.24 ($49.69).

Gerresheimer Stock Up 1.4%

The business has a fifty day moving average of €45.07 and a 200 day moving average of €54.39. The firm has a market cap of $1.50 billion, a P/E ratio of 13.15, a P/E/G ratio of 0.82 and a beta of 0.94. The company has a quick ratio of 0.40, a current ratio of 0.80 and a debt-to-equity ratio of 87.94.

About Gerresheimer

(Get Free Report)

Gerresheimer AG, together with its subsidiaries, manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally. It operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The company offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and glass bottles and jars, as well as caps, closures, applicators, and accessories; development, industrialization and contract manufacturing of drug delivery programs; project and quality management; and drug delivery systems, including inhalers, injection/auto injectors, pen injectors, infusion systems, and inhalation assessment, autoinjector, and other services.

See Also

Should You Invest $1,000 in Gerresheimer Right Now?

Before you consider Gerresheimer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gerresheimer wasn't on the list.

While Gerresheimer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.